Ziva Surgical Rebranded to Advance Breast Cancer Surgery Technology
News related to:Ziva Surgical · 2 min read
PERTH, Australia, Nov. 12, 2026 /CourierPR/ -- OncoRes Medical, an Australian tissue intelligence company, has rebranded as Ziva Surgical, marking a significant shift in its mission to revolutionize breast cancer surgery. The company, which has spent over a decade developing quantitative micro-elastography (QME) technology, is now poised to bring real-time tissue intelligence into the operating room.
Founded in Perth, Ziva Surgical has made substantial progress in advancing its ELORA® System, a technology designed to provide surgeons with quantitative maps of tissue stiffness and microarchitecture during surgery. This innovation aims to help surgeons make more informed decisions about what tissue to remove and what to preserve, ultimately reducing the need for additional operations.
According to Dr. Katharine Giles, CEO of Ziva Surgical, the company's journey began with a small team determined to solve a critical challenge in cancer surgery: ensuring that all cancerous tissue is removed during the initial operation.
Currently, approximately one in five women undergoing breast-conserving surgery face a second operation due to residual cancer. The ELORA® System, powered by QME technology, is intended to complement traditional methods by providing objective, microscale imaging that translates the surgeon's sense of touch into quantitative data. This could help surgeons make more precise decisions, potentially reducing the risk of residual cancer and improving patient outcomes.
The ELORA® System received FDA Breakthrough Device Designation in 2020, underscoring its potential to address unmet medical needs. The system is supported by an exclusive commercial license and more than 44 granted patents globally in key markets across 10 patent families. These patents cover critical aspects of the technology, ensuring Ziva Surgical's intellectual property is protected as it prepares for commercialization.
While initially focused on breast-conserving surgery, Ziva Surgical's longer-term vision extends to other solid tumor cancers, including prostate cancer. Early feasibility studies have shown promising results, indicating that the technology could have broader applications in the future.
As Ziva Surgical advances its clinical development program and prepares for commercialization, the company's evolution reflects a pivotal shift toward bringing real-time tissue intelligence into surgical practice. The company remains committed to its mission of giving surgeons greater clarity when and where it matters most, with the ultimate goal of helping more patients move forward after a single operation.
With its new identity and advanced technology, Ziva Surgical is well-positioned to transform the landscape of cancer surgery, offering a more precise and efficient approach to treating solid tumors.